Loading...

Eli Lilly and Company

LLYNYSE
HealthcareDrug Manufacturers - General
$734.24
$-17.21(-2.29%)

Eli Lilly and Company LLY Peers

See (LLY) competitors and their performances in Stock Market.

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

LLY vs AZN Comparison

LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LLY stands at 695.87B. In comparison, AZN has a market cap of 418.99B. Regarding current trading prices, LLY is priced at $734.24, while AZN trades at $67.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LLY currently has a P/E ratio of 59.84, whereas AZN's P/E ratio is 27.14. In terms of profitability, LLY's ROE is +0.77%, compared to AZN's ROE of +0.19%. Regarding short-term risk, LLY is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.

Loading...

Peer Comparison Table: Drug Manufacturers - General Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
LLY$734.24-2.29%695.87B59.84$12.27+0.73%
AZN$67.57+0.40%418.99B27.14$2.49+2.28%
JNJ$154.20-0.94%371.60B17.13$9.00+3.22%
ABBV$184.55-0.56%326.47B79.21$2.33+3.45%
NVO$65.73+1.35%293.60B19.16$3.43+2.45%
RHHBF$337.03-2.42%254.03B26.88$12.54+3.26%
RHHVF$308.00-1.92%248.89B24.56$12.54+3.55%
RHHBY$38.26-2.17%245.56B24.37$1.57+3.56%
NVS$108.68-1.32%214.65B17.03$6.38+3.67%
AZNCF$135.22+0.84%209.68B30.05$4.50+2.30%
Showing 1 to 10 of 67 results
1

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.